Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Early, aggressive treatment of brain lesions caused by multiple sclerosis could help ward off faster decline in patients, a ...

A short course of Mavenclad can provide long-term reductions in disease activity and disability progression in highly active ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Available disease-modifying therapies can prevent relapses and relapse-associated worsening in people with multiple sclerosis by targeting autoimmunity through various mechanisms. However, these ...

A pharmaceutical and a nonprofit are teaming up to evaluate segesterone acetate as a possible MS therapy to restore lost myelin in patients.

A separate US-based single-arm OLIKOS Phase IIIb study showed that at 12 months, all clinically stable RMS patients who switched from intravenous (IV) anti-CD20 therapy to Kesimpta showed no new ...

A new study exposes the hidden bias behind delayed or denied treatments. It's time to break down these barriers and ensure everyone with #MS gets the care they deserve. ’ Therapeutic inertia ...

The catering manager for a local secondary school explained that making the decision to receive cold cap treatment was one of ...

SAN DIEGO - Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ: HALO) announced today that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™, a new formulation for the treatment ...